Outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as first-line treatment for patients with metastatic or recurrent colorectal cancer

Journal of Korean Medical Science

Volumn 22, Issue 3, 2007, Pages 400-404

  Joon, Ho Moon ^a   Jong, Gwang Kim ^a   Sang, Kyun Sohn ^a   Jin, Ho Baek ^b   Yoon, Young Cho ^a   Yee, Soo Chae ^a   Byung, Min Ahn ^a   Shi, Nae Kim ^a   Soo, Jung Lee ^a   In, Taek Lee ^a   Gyu, Seog Choi ^a   Soo, Han Jun ^a  

^a Kyungpook National University Hospital   (South Korea)

^b Dongguk University   (South Korea)

Author keywords

Colorectal neoplasms; Fluorouracil; Leucovorin; Oxaliplatin

Indexed keywords

EID: 34447132926     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2007.22.3.400     Document Type: Article

References (16)

1. American Cancer Society: Cancer Facts and Figures-2000. American Cancer Society, Atlanta, GA, 2000.
2. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808-15.
3. Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003; 21: 2896-903.
4. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
5. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-47.
6. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-69.
7. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
8. Nancy K, Carlos AG, Jayne G, Howard H, Peter K, Al B, Debra SB, Jonathan P, Michael W, Grace S, Doreen H, Brent B, Sunil G. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 2004; 22: 4753-61.
9. Yves B, Erick G, Bruno C, Sylvie N, Jean-Yves P, Jean-Luc R, Jocelyne P, Olivier R, Claude K, Caroline G, Mohamed B, Dominique M, Mireille M. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 2001; 19: 4195-201.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
11. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
12. Ramanathan RK, Clark JW, Kemeny NE, Lenz HJ, Gococo KO, Haller DG, Mitchell EP, Kardinal CG. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol 2003; 21: 2904-11.
13. Andre T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, Beerblock K, Bouche O, Carola E, Merrouche Y, Morvan F, Dupont-Andre G, de Gramont A. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999; 17: 3560-8.
14. Kwon HC, Kim KT, Lee SA, Park JS, Kim SH, Kim JS, Kim HJ. Oxaliplatin with biweekly, low dose leucovorin and bolus and continuous Infusion 5-fluorouracil (Modified FOLFOX 4) as First-line therapy for patients with metastatic colorectal cancer. Cancer Research Treatment 2004; 36: 115-20.
15. Shin YM, Han HS, Lim SW, Kim BC, Cheoi KS, Eum YO, Kim ST, Lee KH. Combination chemotherapy of oxaliplatin, 5-fluorouracil and low dose leucovorin in patients with advanced colorectal cancer. Cancer Res Treat 2005; 37: 284-9.
16. Lee JH, Kim TW, Lee KH, Kang YK, Lee JS, Kim SH, Kim HC, Yu CS, Kim JC, Kim WK. Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer. J Korean Med Sci 2001; 16: 69-74.